List view / Grid view
Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer.
In this Q&A, Krishna Polu and Dennis Pedersen, senior leaders of Commit Biologics, which is backed by Novo Holdings and Bioqube Ventures, elucidate how their technology differs from other existing therapeutic platforms and highlight its implications for the treatment of both cancer and autoimmune disease.
Discover how Cue Biopharma harnesses the curative potential of the body’s intrinsic immune system to develop treatments for oncology and autoimmune diseases. Here, Anish Suri, Chief Scientific Officer of Cue Biopharma, explains how its platforms and biologics are designed to selectively modulate disease-specific T cells to restore immune balance, aiming…
KDR inhibitors could be very impactful for treatment of ATLL and HAM/TSP or prevent disease by lessening the viral load of HTLV-1.
Blocking the TGF-β signalling pathway produced effective antitumour activity against hepatocellular carcinoma.
Researchers screened over 2,000 small molecules and have now more than doubled the known compounds reported to induce trained immunity.
In this exclusive interview with Elicio Therapeutics, we explore the transformative potential of liquid biopsy in oncology drug development, particularly spotlighting its application in Elicio’s AMPLIFY-201 study of ELI-002, a promising therapeutic cancer vaccine candidate.
Targeted alpha therapy shows promising preclinical results, increasing survival rate by 36.4 percent in recurrent tumours.
At the heart of precision oncology is the need to increase our understanding and knowledge of surface proteins found on tumour cells. Here Roman Thomas, CEO of DISCO Pharmaceuticals, explains how it is using cutting-edge technology to explore the surfaceome – a map of the proteins on the cell’s surface…
Understanding how MMR-deficient colorectal cancers drive tumour growth and avoid immune detection could pave the way for personalised cancer medicine.
Researchers found that tumour beta cells lose their repression marks and express elevated levels of oncogenes.
Molecular, cellular and metabolic analyses of liver biopsies identified markers that may predict subsequent metastasis of pancreatic cancer.
The tool identified patients with high-risk disease, which normally goes unrecognised by traditional diagnostics.
The inhibitor, HVH-2930, effectively induced apoptosis in breast cancer cells without initiating the heat shock response.
A novel screening tool may increase the five-year survival rate of hepatocellular carcinoma patients to 90 percent.
Researchers have developed a 3D approach to improve the characterisation of pancreatic intraepithelial neoplasias.
